Karo Healthcare enters an exclusive license agreement with Moberg Pharma for MOB-015 in Europe

Karo Healthcare AB (“Karo”) has entered an exclusive licensing agreement with Moberg Pharma AB (“Moberg Pharma”) regarding the commercialisation of…

Karo Healthcare appoints Konstanze Gallinatus as Chief Transformation Officer

Karo Healthcare (“Karo”) has appointed Konstanze Gallinatus as Chief Transformation Officer and member of the Corporate Management Team. The appointment…

Karo Healthcare strengthens its portfolio of skin health brands in Northern Europe

Following the closing of KKR’s acquisition of Karo Healthcare (“Karo”) on 27 August, Karo today confirms that the agreement to…

Karo Group publishes the 2024 Sustainability Report

Today, on 15 April 2025, Karo Group* is publishing its 2024 Sustainability Report on the company’s website, www.karohealthcare.com. For further…

Karo Healthcare announces KKR as new owner, following successful strategic transformation into pan-European consumer healthcare player

Karo Healthcare (“Karo”) will change owner following the announcement that EQT has agreed to sell Karo to funds managed by…

Karo Healthcare appoints Egil Molsted Madsen as CFO

We are pleased to announce that Egil Molsted Madsen will assume the role of CFO at Karo starting on 3…

Karo Healthcare appoints Egil Mølsted Madsen as CFO

We are pleased to announce that Egil Mølsted Madsen will assume the role of CFO at Karo starting on 3…

Karo Group publishes the 2023 Sustainability Report

Today, on 15 April 2024, Karo Group* is publishing its 2023 Sustainability Report on the company’s website, www.karohealthcare.com. For further…

Karo Healthcare expands its presence in Italy with the acquisition of the rights to Proctosedyl® from Bayer

Karo Healthcare AB (‘Karo’) announces the acquisition of the rights to the OTC brand Proctosedyl from Bayer. The transaction transfers…

Karo Healthcare completes the acquisition of the rights to the Global OTC brand Lamisil® from Haleon

Karo Healthcare (‘Karo’) has today completed the previously announced acquisition of the rights to the Global OTC brand Lamisil® from…

Karo Healthcare acquires the Global OTC brand Lamisil® from Haleon

Karo Healthcare (‘Karo’) announces the acquisition of the rights to the Global OTC brand Lamisil® from Haleon UK Holdings Ltd.…

Babak Peyami Joins Karo’s Corporate Management Team as new Head of Digital Commerce

Karo Healthcare announces changes to its Corporate Management Team. Robin List transitions to an advisory role and Babak Peyami is…

Karo Healthcare publishes the 2022 Sustainability Report

Today, on 24 April 2023, Karo Healthcare is publishing its first separate Sustainability Report on the company’s website, www.karohealthcare.com. For…

Financial Report 2022

Michael Kaltenborn appointed CSDO at Karo

Karo Healthcare (“Karo”) has appointed Michael Kaltenborn as Chief Strategy & Corporate Development Officer (CSDO). The appointment of Michael Kaltenborn…

Karo Pharma Aktiebolag’s application for de-listing has been approved

Karo Pharma Aktiebolag’s (“Karo Pharma” or the “Company”) application for de-listing has now been approved by Nasdaq. The last day…

Karo Pharma Aktiebolag applies for de-listing

The Board of Directors of Karo Pharma Aktiebolag (“Karo Pharma” or the “Company”) has resolved to apply for de-listing of…

Karo Intressenter AB initiates compulsory redemption

On 16 August 2022, Karo Intressenter AB[1] (“Karo Intressenter”) announced a public cash offer to the shareholders in Karo Pharma…

Karo Pharma Aktiebolag comments on the public offer from Karo Intressenter AB and obtains a fairness opinion

Background On 16 August 2022, Karo Intressenter AB1 (“Karo Intressenter”) announced a public cash offer to the shareholders in Karo…

Comment from Karo Pharma Aktiebolag’s board of directors regarding the public offer from Karo Intressenter AB

Today, on 16 August 2022, Karo Intressenter AB1 (“Karo Intressenter”) announced a public cash offer to the shareholders in Karo…

Interim report H1 2022

January – June · Revenues amounted to MSEK 1 965.3 (1 460.9), corresponding to an increase of +35% for the…

Karo Pharma enters into an agreement for the potential acquisition of the E45® brand from Reckitt

Karo Pharma Aktiebolag (“Karo”) has today entered into a put option agreement pursuant to which it may acquire the dermatology…

Karo Pharma intends to change listing venue to Nasdaq First North Growth Market during the first half of 2022

The board of directors of Karo Pharma Aktiebolag (publ) (the ”Company” or ”Karo”) has resolved to initiate a process to…

Karo Pharma acquires Sylphar International NV for EUR 290m and intends to carry out a rights issue of approximately EUR 200-250m

Karo Pharma Aktiebolag (publ) (the ”Company” or ”Karo”) has today entered into an agreement to acquire all of the shares…

Karo Pharma Quarterly report Q3 2021

July – September Revenues amounted to MSEK 738.5 (679.1), corresponding to an increase of +9% for the period. The organic…

Anna Hale appointed CMO at Karo Pharma

Karo Pharma Aktiebolag (publ) (“Karo”) has appointed Anna Hale as the Chief Marketing Officer (CMO) of Karo. The appointment reflects Karo’s growth ambitions, fueled by a…

Magnus Nylén leaves Karo Pharma, Matt Roberts appointed new CCO

Karo Pharma Aktiebolag (“Karo”) has appointed Matt Roberts as the new Chief Commercial Officer (CCO) of Karo, replacing Magnus Nylén…